Latest News on SYK

Financial News Based On Company


Advertisement
Advertisement

Stryker Sticks to Growth Goals Despite Cyberattack and Slower Orthopedic Market

https://www.tradingview.com/news/marketbeat:8702a27e3094b:0-stryker-sticks-to-growth-goals-despite-cyberattack-and-slower-orthopedic-market/
Stryker expects to maintain its long-term growth and margin goals despite a recent cyberattack, supply chain disruptions, and a softer U.S. orthopedic market. The company plans to achieve these goals through efficiency improvements, product transfers, and strategic acquisitions, with most cyberattack effects expected to remain in 2026. Executives also noted continued strong hospital capital demand and plans for modest share repurchases and dividend growth.

Stryker stock keeps robot production in U.S. over IP concerns

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-keeps-robot-production-in-u-s-over-ip-concerns/70536183
Stryker CEO Kevin Lobo announced the company will continue to produce orthopedic surgical robots in the United States due to significant intellectual property concerns, particularly regarding China. This decision underscores the growing importance of robotics in Stryker's orthopedic business, with the Mako system now used in two out of three knee replacements. Additionally, Stryker is expanding into soft-tissue robotic surgery through a strategic investment in CMR Surgical, securing exclusive U.S. sales rights for its Versius system.

MedTech poised to outperform in 2027, Leerink says as Abbott upgraded

https://seekingalpha.com/news/4674781-abbott-stock-upgraded-leerink-medtech-potential
Leerink Partners upgraded Abbott Laboratories (ABT) to Outperform, anticipating significant gains for the MedTech sector over the next 12–24 months. The firm expresses growing conviction that MedTech will deliver outsized returns, driven by multiple favorable factors. This upgrade suggests a positive outlook for Abbott and the broader medical technology industry.

Earnings Beat Might Change The Case For Investing In Stryker (SYK)

https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/earnings-beat-might-change-the-case-for-investing-in-stryker
Stryker (SYK) reported strong third-quarter results with 10.3% adjusted EPS growth driven by margin gains and cost control, particularly from Endoscopy, Medical, and Mako orthopaedics. The company is focusing on robotics and strategic board appointments to support its defensive growth narrative. Despite ongoing operational and sentiment risks like debt and insider selling, the latest performance indicates that Stryker's strategy remains effective.

Stryker (SYK) Keeps Knee Robot Production In The US And Expands Robotic Surgery

https://sg.finance.yahoo.com/news/stryker-syk-keeps-knee-robot-051745564.html
Stryker (SYK) is maintaining the production of its knee surgery robots in the U.S., citing intellectual property protection as the primary reason. The medical technology company is also expanding into soft-tissue robotic surgery through a new partnership with CMR Surgical, which includes U.S. distribution rights. This strategic focus on localized production and broader robotic surgery offerings is central to Stryker's investment narrative, aiming to support revenue and margin expansion through high-value procedures.
Advertisement

Agilent Technologies Replaces Retiring Board Member With Former Stryker Executive

https://www.mpo-mag.com/breaking-news/agilent-technologies-replaces-retiring-board-member-with-former-stryker-executive/
Agilent Technologies has announced changes to its Board of Directors, with Koh Boon Hwee retiring after over two decades of service. Dow R. Wilson, who has been on the board since 2018, will replace him as independent chair. Additionally, Glenn Boehnlein, formerly CFO of Stryker Corporation, has been appointed to the board, bringing extensive financial and medical technology sector experience.

Sintx Technologies, Inc. (SINT) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/SINT/
Sintx Technologies, Inc. (SINT) stock closed at $1.2050, down 2.82%, with a market cap of $9.108 million. The company, which specializes in silicon nitride biomaterials for medical and other applications, has seen significant negative returns over the past year, with a 1-year return of -63.48% and a 5-year return of -99.99%. Analysts maintain a "Buy" rating with a target price of $12.50.

CVS Health Corp Stock (CVS) Moved Down by 3.26% on Nov 17: What Signal Does It Send?

https://www.tradingkey.com/news/market-movers/262309679-market-movers-cvs-20261117
CVS Health Corp's stock (CVS) fell 3.26% on November 17, driven by investor concerns about medical cost trends in its managed care division and ongoing challenges in the retail pharmacy sector. The company's valuation is sensitive to utilization patterns in its Aetna health benefits business, with elevated outpatient procedure volumes and tightened government reimbursement rates impacting margins. Analysts maintain an average price target of $111.25 for CVS, despite the current downward pressure.

Medtronic’s Hugo robot gets expanded FDA clearance in general surgery

https://www.medtechdive.com/news/medtronics-hugo-robot-gets-expanded-fda-clearance-in-general-surgery/874904/
Medtronic's Hugo robotic surgery system has received expanded FDA clearance for use in general surgery procedures, including upper and lower abdominal surgeries. This clearance significantly broadens Hugo's market reach, covering over half of the soft tissue procedures performed annually in the U.S. Medtronic aims to leverage its existing expertise in general surgery to further penetrate the robotic surgery market, where it is experiencing rapid global growth with its Hugo system.

Stryker stock: gains 2.64% above prior Xetra close

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-gains-2-64-above-prior-xetra-close/70527597
Stryker stock (SYK) saw a 2.64% gain above its prior Xetra close, trading at 289.40 euros on November 17, 2026. This move also placed the medical-device maker's shares 2.37% higher than an earlier quote from the same day. The company's performance is closely tied to its operating outlook and procedure volumes in orthopaedics, surgery, and other medical applications.
Advertisement

Stryker stock: Management reaffirms growth targets at Jefferies

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-management-reaffirms-growth-targets-at-jefferies/70527167
Stryker's management reaffirmed its long-term growth targets at the Jefferies Global Healthcare Conference, with incoming CEO Spencer Stiles outlining priorities focused on accelerating growth and simplifying operations. The company expects cyber-related disruptions to subside in 2026, leading to stronger comparisons in 2027, and continues to target significant operating margin expansion and free-cash-flow conversion. Despite some softness in the orthopedic market, strong capital equipment demand and a robust product pipeline position Stryker for future growth, with M&A remaining its top capital allocation priority.

ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?

https://www.tradingview.com/news/zacks:27ed14d4d094b:0-isrg-eps-climbs-25-to-3-is-innovation-driving-profitable-growth/
Intuitive Surgical (ISRG) reported strong adjusted earnings growth in Q3 2026, with EPS up 25% to $3 and revenue increasing 22% to over $3 billion, driven by the adoption of its robotic platforms and improved operating efficiency. The company continues to invest heavily in innovation, including AI capabilities for its da Vinci 5 system and new instrumentation, which is reflected in increased R&D expenses. While adjusted profit rose significantly, GAAP net income declined due to a $450 million litigation settlement.

DeGen Medical Moves to Dismiss Carlsmed Patent Suit, Vows to Fight Remaining Claims

https://www.manilatimes.net/2026/11/16/tmt-newswire/globenewswire/degen-medical-moves-to-dismiss-carlsmed-patent-suit-vows-to-fight-remaining-claims/2470409
DeGen Medical has filed a motion to dismiss key parts of a patent infringement lawsuit brought by Carlsmed. DeGen argues that Carlsmed's asserted method claims are patent-ineligible abstract ideas and is also seeking dismissal of willfulness allegations and enhanced damages. The company stated its commitment to defending its human-centered approach to patient-specific implants, which contrasts with Carlsmed's automated methods.

Stryker’s next CEO has an AI agent named Ray (but had to fire another named Bob)

https://www.medicaldesignandoutsourcing.com/stryker-ceo-spencer-stiles-ai-agent-ray/
Incoming Stryker CEO Spencer Stiles uses an AI agent named Ray for personal productivity and to understand how AI can be integrated into the workplace. He attempted to create another AI assistant, Bob, to serve as a chief of staff, but quickly "fired" it after it suggested he tell his real-life assistant what she could be doing better. Stiles emphasizes the importance of embracing AI for himself to better communicate its potential to Stryker's 58,000 employees, highlighting its current use in R&D, surgical planning, and care environment monitoring.

Is Abbott Laboratories (ABT) Undervalued On Medical Devices Growth And New Rapid Tests?

https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-undervalued-on-medical-devices-gr
Abbott Laboratories (ABT) is gaining attention due to momentum in its Medical Devices unit, particularly with electrophysiology products and new rapid testing offerings. Despite a 12.62% year-to-date share price decline, analysts consider ABT undervalued with a fair value of $120.26, contingent on continued growth in medical technology and managing Nutrition legal risks. However, its P/E ratio of 40.2x is higher than industry averages, suggesting limited upside if market sentiment shifts.
Advertisement

GEHC or SYK: Which Is the Better Value Stock Right Now?

https://finance.yahoo.com/markets/stocks/articles/gehc-syk-better-value-stock-154003651.html
This article evaluates GE HealthCare Technologies (GEHC) and Stryker (SYK) to determine which is a better value stock. Utilizing Zacks' Style Scores and Rank, it concludes that GEHC is the superior value option due to its #2 (Buy) Zacks Rank, more impressive earnings estimate revision activity, and better valuation metrics such as a lower forward P/E and P/B ratio compared to SYK's #4 (Sell) Rank.

Fund Update: 866,832 STRYKER (SYK) shares added to GENERATION INVESTMENT MANAGEMENT LLP portfolio

https://www.quiverquant.com/news/Fund+Update%3A+866%2C832+STRYKER+%28SYK%29+shares+added+to+GENERATION+INVESTMENT+MANAGEMENT+LLP+portfolio
GENERATION INVESTMENT MANAGEMENT LLP has added 866,832 shares of STRYKER (SYK) to its portfolio, as per a recent SEC 13F filing for the 09-30-2026 report period. The article details other institutional investor activity, insider trading, and Congressional stock trades related to SYK, highlighting a mix of buys and sells by various entities. It also includes recent analyst ratings and price targets, predominantly showing "Buy" or "Overweight" recommendations.

CONMED at Jefferies Global Healthcare Conference: growth drivers build By Investing.com

https://ca.investing.com/news/stock-market-news/conmed-at-jefferies-global-healthcare-conference-growth-drivers-build-93CH-4960412
CONMED Corporation outlined its business strategy at the Jefferies Global Healthcare Conference, emphasizing steady growth driven by stable demand in core markets, strong adoption of key products like AirSeal and Buffalo Filter, and new legislative support for smoke evacuation. The company expects mid-single-digit revenue growth and approximately 10% EPS growth, but anticipates cost pressures from raw materials and freight in 2027. Management also discussed the transition period for BioBrace in the U.S. and its M&A strategy, aiming for further deleveraging while considering acquisitions in general surgery and orthopedics.

Stryker (SYK) Board Refresh And Financing Flexibility Put Valuation Back In Focus

https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/stryker-syk-board-refresh-and-financing-flexibility-put-valu
Stryker (SYK) is undergoing a board refresh with a new director joining in early 2027 and has filed a shelf registration for future financing flexibility. This comes as the company's stock has been under pressure, with shares down over 11% year-to-date. Despite the market's skepticism, the article highlights Stryker's strong earnings growth, robust cash flow, and positioning in the medical technology sector, suggesting a potential sentiment reset rather than a fundamental flaw in the business.

Earnings Beat Could Be A Big Moment For Abbott Stock And Nutrition Split Plans

https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/earnings-beat-could-be-a-big-moment-for-abbott-stock-and-nut
Abbott Laboratories recently reported strong third-quarter 2026 sales and earnings across key segments and announced plans to spin off its global Nutrition business into a separate public company by late 2027. The company's focus is now on how this spin-off and its medical devices pipeline will reshape its investment narrative, alongside ongoing efforts in diagnostics and margin expansion. Analysts are watching for execution on margins and the concentration of risk related to the Nutrition segment, while new product launches like the Panbio COVID-19/Flu A&B Self Test contribute to the diagnostics growth story.
Advertisement

Edwards Lifesciences Corporation (EW) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/EW/
Edwards Lifesciences Corporation (EW) stock is currently trading at $107.15, up 1.28%, with an after-hours price of $106.50. The company, a medical device provider specializing in cardiovascular diseases, has seen a YTD return of 25.69% and a 1-year return of 24.43%. Analysts have an average price target of $113.39, with TD Cowen recently raising its price target to $121 and maintaining a Buy rating.

CNSY - Cerenome Inc. stock news, filings & ratings | Quantisnow

https://www.quantisnow.com/company/CNSY
Cerenome Inc. (CNSY) is a CNS oncology company listed on NASDAQ, specializing in precision diagnostics, targeted therapeutics, and AI for central nervous system cancers. The company's stock recently saw a significant jump (+46.65%) and has been active with news including a new Chief Business Officer appointment, an in-network agreement with Aetna for its CNSide® Diagnostics platform, and an upcoming conference call to discuss clinical data and Q3 2026 financial results. Financially, Cerenome reported $4.20M in revenue for the last twelve months and a net loss of $26.09M.

Stryker Corp. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/stryker-corp-stock-underperforms-thursday-when-compared-to-competitors-62870f79-e4ffba1c2a5a
Stryker Corp. (SYK) shares fell 2.01% to $312.39 on Thursday, marking its sixth consecutive day of losses. This underperformance occurred during a generally rough trading session where the S&P 500 Index and Dow Jones Industrial Average also saw declines.

Former Medtronic and Baxter International Executives Join Chapman & Co. Leadership Institute, Expanding Healthcare and MedTech Expertise

https://www.newswire.com/news/former-medtronic-and-baxter-international-executives-join-chapman-co-22888466
Chapman & Co. Leadership Institute has announced the addition of Jeanne Mason, former executive vice president and chief human resources officer of Baxter International, and Carla Skinner, former senior director of Medtronic's Global Sales Excellence, to its senior leadership team. This expansion aims to bolster the firm's expertise in healthcare, life sciences, and MedTech organizations, bringing decades of experience in leadership development, culture transformation, and organizational change. Their appointments are set to enhance the consultancy's ability to help clients align strong culture with robust business results in complex and highly regulated industries.

Stryker stock slips as 2026 outlook is cut

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-slips-as-2026-outlook-is-cut/70492662
Stryker's stock slipped after the company reduced its 2026 sales and earnings outlook, leading to investor concerns about execution. The company lowered its full-year organic sales growth target to 6.5%-7.0% from a previous 8.3%-9.3%, and adjusted earnings per share guidance was also reduced. This downward revision occurred despite stronger adjusted margins, with management attributing the shift to third-quarter performance falling short of expectations due to weaker hip and knee procedure trends and supply constraints.
Advertisement

Have Insiders Sold Stryker Shares Recently?

https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/have-insiders-sold-stryker-shares-recently-3
Independent Director Ronda Stryker recently sold US$179 million worth of Stryker Corporation (NYSE:SYK) shares, reducing her holding by 3.8%. This follows an even larger sale earlier in the year, though both transactions were at prices above the current share price of US$324. While there have been no insider purchases in the last year, Stryker maintains high insider ownership at 9.2%, valued at US$11 billion, and is experiencing earnings growth.

Spectral AI - Class A Share News - Latest Updates, Live News & More

https://scanx.trade/us-stock-news/MDAI-spectral-ai-inc
Spectral AI's latest news indicates a challenging Q3 FY26 with sales missing estimates, despite EPS beating consensus. The company's revenue declined by 24.7% year-over-year, leading to a lowered full-year revenue guidance. However, Spectral AI secured significant non-dilutive funding and continues to showcase its DeepView System, which recently received FDA De Novo Classification and UKCA authorization, with commercial sales expected by the end of 2026.

Stryker Board Expands with Healthcare Executive James Davis

https://www.theglobeandmail.com/investing/markets/stocks/SYK/pressreleases/8769863/stryker-board-expands-with-healthcare-executive-james-davis/
Stryker's board of directors has been expanded from 11 to 12 members with the election of James E. Davis. Davis, the CEO and President of Quest Diagnostics, brings extensive experience from across the healthcare, medical technology, and global operations sectors. Analysts maintain a "Buy" rating on Stryker (SYK) stock with a $350.00 price target, while TipRanks' AI Analyst, Spark, rates SYK as "Outperform" due to strong financial performance.

Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates

https://www.globenewswire.com/news-release/2026/11/10/3400189/21634/en/stereotaxis-reports-2026-third-quarter-financial-results-business-updates.html
Stereotaxis (NYSE: STXS) reported a 20% increase in third-quarter 2026 revenue to $8.9 million, driven by strong system sales and growth in robotically-navigated catheters. The company is focusing on transitioning to more accessible and scalable systems and developing disposable interventional catheters for recurring revenue. Stereotaxis also announced a convertible note financing of up to $24 million to bolster its cash balance and support future growth.

Autonomix Medical receives new U.S. patent for catheter sensing technology

https://www.streetinsider.com/Corporate+News/Autonomix+Medical+receives+new+U.S.+patent+for+catheter+sensing+technology/27322522.html
Autonomix Medical announced the issuance of a new U.S. Patent for "Medical Devices With Circuitry For Capturing And Processing Physiological Signals." This patent strengthens the intellectual property for their catheter sensing technology, which is designed for high-resolution sensing and real-time physiological monitoring near the biological source. The company believes this technology could have applications in various medical procedures, though it is currently investigational and not cleared for marketing.
Advertisement

Christine Poole’s Top Picks: Microsoft, RTX Corp & Stryker

https://www.bnnbloomberg.ca/video/shows/market-call/2026/11/10/christine-pooles-top-picks-microsoft-rtx-corp-stryker/
Christine Poole, president and co-chief investment officer at Davis Rea, shared her top stock picks for investors to watch in the market. Her selections include Microsoft, RTX Corp, and Stryker. The article presents these as her recommended investments.

Is Current Price Of Stryker Stock A Strong Support?

https://www.trefis.com/stock/syk/articles/623943/is-current-price-of-stryker-stock-a-strong-support/2026-11-10
Stryker (SYK) stock has seen a 6.9% decline over the past year, trading near a price point ($325.73) where it bounced strongly in 2024 but has since fallen 5% on subsequent returns. While Stryker's strong operating margin and organic sales growth in MedSurg and Neurotechnology offer a plausible reason for a bounce, a slowing hip and knee business and execution risk on capital equipment sales pose a significant threat, potentially pushing the stock to the next support level at $293.30. Investors should watch for fourth-quarter organic sales growth and improvements in U.S. knee and hip sales in the upcoming January 2027 earnings report.

Stryker stock faces pressure after 2026 outlook cut

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-faces-pressure-after-2026-outlook-cut/70487152
Stryker lowered its full-year 2026 organic sales and adjusted earnings outlook after third-quarter performance fell short of expectations. Despite the cut, the company saw sales growth and stronger adjusted profitability, with adjusted net earnings increasing by 10.1 percent. The revised guidance places increased focus on procedure volumes, Orthopaedics execution, and margin expansion for investors.

Intuitive Surgical Inc Stock (ISRG) Moved Down by 3.35% on Nov 10: Drivers Behind the Movement

https://www.tradingkey.com/news/market-movers/262299098-market-movers-isrg-20261110
Intuitive Surgical Inc (ISRG) stock declined by 3.35% on November 10 due to macro pressures, institutional de-risking, and concerns over hospital capital expenditures and surgical procedure volume growth. Despite this, the company maintains a strong robotic surgery ecosystem, recurring revenue, and robust balance sheet. Technical indicators are largely neutral, and analysts have a "Buy" rating with an average price target of $486.97.

Enovis (NYSE:ENOV) Q3 2026: Recon Growth, Guidance Raised

https://kalkinemedia.com/us/stocks/healthcare/enovis-nyseenov-q3-2026-recon-growth-guidance-raised
Enovis (NYSE:ENOV) reported strong Q3 2026 results, with sales growth on both reported and organic bases, driven by significant market share gains in its Reconstructive segment. The company also raised its full-year guidance for adjusted EBITDA and adjusted EPS, reflecting confidence in margin improvement and successful execution of its innovation-led strategy. This performance highlights Enovis's ability to capitalize on steady demand from an aging population and advancements in orthopedic medical technology.
Advertisement

Ronda E Stryker Executes Sell Order: Offloads $178.92M In Stryker Stock

https://www.benzinga.com/news/26/11/63094224/ronda-e-stryker-executes-sell-order-offloads-178-92m-stryker-stock
Ronda E Stryker, a Director at Stryker (NYSE: SYK), sold 550,000 shares of the company's stock for a total of $178.92 million on November 9. The article provides an overview of Stryker's financial performance, including revenue growth, profitability metrics, and debt management, and discusses the importance of insider transactions for investors. Stryker's shares were down by 1.86% to $319.66 following the disclosure.

Stryker stock outlook cut after Q3 growth misses expectations

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-outlook-cut-after-q3-growth-misses-expectations/70486436
Stryker's stock outlook for 2026 has been lowered after its third-quarter performance, despite solid sales growth, fell short of management's expectations. While adjusted margins and sales growth partly offset weaker reported earnings due to a significant goodwill impairment, the company reset its organic net sales growth and adjusted diluted earnings per share guidance downwards. This shift places increased pressure on the recovery of joint-replacement demand and execution for investors.

Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone

https://www.joplinglobe.com/region/national_business/sensus-healthcare-announces-sale-of-1-000th-srt-system-marking-significant-commercial-milestone/article_15e023a0-dc84-5645-bbca-051d23680d2c.html
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced the sale of its 1,000th superficial radiotherapy (SRT) system, a major commercial milestone. This achievement underscores the company's commitment to providing non-invasive treatment options for non-melanoma skin cancer and reflects increased physician awareness and dedicated reimbursement codes for SRT. Sensus Healthcare plans to continue expanding access to this technology, aiming for the next 1,000 units.

519,163 Shares of Stryker Corporation $SYK Acquired by Welch & Forbes LLC

https://www.marketbeat.com/instant-alerts/filing-519163-shares-of-stryker-corporation-syk-acquired-by-welch-forbes-llc-2026-11-10/
Welch & Forbes LLC has acquired a significant new stake in Stryker Corporation (NYSE:SYK), purchasing 519,163 shares valued at approximately $142.97 million during the third quarter. This acquisition makes Stryker the 14th largest position in Welch & Forbes LLC's portfolio, representing about 1.7% of its total holdings. The article also details recent insider selling activity and updated analyst price targets for Stryker.

Orthofix Q3 Revenue Misses Estimates by $2.62 Million as EPS Beats

https://www.tokenpost.com/news/business/52908
Orthofix Medical Inc. reported third-quarter revenue of $207.9 million, missing analyst estimates by $2.62 million, despite a 1.1% year-over-year increase. The company's GAAP loss per share of $0.15 was 12 cents better than expected. Cash and cash equivalents decreased sequentially to $86.9 million from $104.4 million due to working-capital timing.
Advertisement

Stryker (NYSE:SYK) Stock: Insider Ronda Stryker Sells 550,000 Shares

https://www.marketbeat.com/instant-alerts/insider-stryker-nyse-syk-stock-insider-ronda-stryker-sells-550000-shares-2026-11-09/
Stryker Director Ronda Stryker sold 550,000 shares of SYK stock for approximately $178.9 million, reducing her holdings by 24.43%. This insider sale follows Stryker's recent quarterly results that missed earnings and revenue expectations, although revenue still grew 7.6% year-over-year. Despite several analysts lowering their price targets or ratings, the consensus view on the stock remains a "Moderate Buy."

Stryker nominates Quest Diagnostics CEO to board

https://www.investing.com/news/company-news/stryker-nominates-quest-diagnostics-ceo-to-board-93CH-5013217
Stryker's board of directors has nominated Jim Davis, the current Chairman, CEO, and President of Quest Diagnostics, for election to its board, effective January 1, 2027. Davis brings extensive healthcare experience, operational leadership, and medical technology understanding from his previous roles at InSightec, General Electric, and McKinsey & Company. Stryker's Chair and CEO, Kevin Lobo, highlighted Davis's expertise as a strong addition to the company's strategic advancement.

Stryker announces intention to nominate Jim Davis to board of directors

https://www.globenewswire.com/news-release/2026/11/09/3398968/0/en/stryker-announces-intention-to-nominate-jim-davis-to-board-of-directors.html
Stryker (NYSE:SYK) announced its intention to nominate Jim Davis, Chairman, CEO, and President of Quest Diagnostics, to its board of directors, effective January 1, 2027. Davis brings extensive leadership experience from healthcare, medical technology, and global operations, including previous roles at InSightec, Inc., General Electric, and McKinsey & Company, Inc. Kevin Lobo, Stryker's Chair and CEO, highlighted Davis's deep healthcare experience, operational leadership, and understanding of medical technology as valuable additions to the company's strategic advancement.

Stryker nominates Quest Diagnostics CEO Jim Davis to its board

https://www.streetinsider.com/Board+Changes/Stryker+nominates+Quest+Diagnostics+CEO+Jim+Davis+to+its+board/27314889.html
Stryker has nominated Jim Davis, the current Chairman, CEO, and President of Quest Diagnostics, to its board of directors, effective January 1, 2027. Davis brings extensive healthcare, operational, and medical technology experience from his roles at Quest, InSightec, GE, and McKinsey & Company. Kevin Lobo, Stryker's Chair and CEO, expressed enthusiasm for Davis's potential contributions to the company's strategy and mission.

Stryker stock faces lower 2026 outlook after Q3 earnings miss

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-faces-lower-2026-outlook-after-q3-earnings-miss/70482027
Stryker Corp. has lowered its full-year 2026 outlook following a third-quarter performance that fell short of management expectations, despite reporting stronger sales growth. While adjusted operating margin expanded, a goodwill impairment impacted reported earnings. The company now forecasts reduced organic sales growth and adjusted diluted earnings per share, raising execution pressure for investors.
Advertisement

Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel

https://www.newswire.com/news/regentis-signs-exclusive-distribution-agreement-with-ami-technologies-to
Regentis Biomaterials Ltd. announced an exclusive four-year distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC, its knee cartilage repair implant, in Israel. This agreement includes minimum purchase commitments, with initial revenue contributions anticipated in 2027. GelrinC is approved in Israel and Europe, and is currently undergoing a pivotal U.S. Phase III trial, positioning this deal as a key step in Regentis's global commercialization strategy.

Stryker stock faces impairment focus after Q3 outlook cut

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-faces-impairment-focus-after-q3-outlook-cut/70481318
Stryker's stock is under scrutiny after the company reported a significant goodwill impairment of $293 million in its third-quarter earnings, alongside a reduced 2026 outlook. While sales grew 7.7%, net income declined 12.3%, raising questions about earnings quality. The company's recent shelf registration also provides capital flexibility but introduces additional considerations for investors regarding future financing decisions.

A four-year exclusive Israel deal has Regentis (RGNT) expecting revenue contributions.

https://www.stocktitan.net/sec-filings/RGNT/6-k-regentis-biomaterials-ltd-current-report-foreign-issuer-838562fb2c70.html
Regentis Biomaterials Ltd. (RGNT) has signed a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. to commercialize its GelrinC implant in Israel, with initial revenue contributions expected in 2027. The agreement includes minimum purchase requirements and leverages AMI's established network with orthopedic surgeons, hospitals, and clinics. GelrinC, which has Israeli and European regulatory approval, is also being evaluated in a pivotal U.S. Phase III study.

Stryker (NYSE:SYK) Price Target Raised to $350.00

https://www.marketbeat.com/instant-alerts/analyst-stryker-nyse-syk-price-target-raised-to-35000-2026-11-09/
Piper Sandler has increased its price target for Stryker (NYSE:SYK) to $350.00 from $325.00, maintaining an "overweight" rating and suggesting a 7.6% upside. Despite the positive analyst sentiment, the medical technology company recently reported quarterly results slightly below estimates, with EPS of $3.52 versus $3.55 expected and revenue of $6.52 billion against $6.62 billion anticipated, though revenue still grew 7.6% year-over-year. The consensus among analysts remains a "Moderate Buy" with an average target price of $342.19.

Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday

https://www.benzinga.com/analyst-stock-ratings/price-target/26/11/63030017/block-to-rally-over-19-here-are-10-top-analyst-forecasts-for-monday
Top Wall Street analysts have updated their ratings and price targets for several key companies. Notable changes include BTIG raising Magnite Inc's price target, Piper Sandler lowering Unusual Machines Inc's target, and Stifel downgrading DraftKings Inc to Hold. Additionally, Rothschild & Co upgraded Airbnb Inc, while Cantor Fitzgerald raised Block, Inc.'s price target.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement